Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0.00 | $320K |
| Gross profit | — | — | -$2.27M | — | — | — |
| Operating income | -$8.32M | -$26.6M | -$34.5M | -$17.1M | -$27.2M | -$12.6M |
| Operating margin | — | — | — | — | — | -3939.1% |
| Net income | -$6.62M | -$26.6M | -$16.1M | -$11.9M | -$24.5M | -$11.2M |
| Net margin | — | — | — | — | — | -3509.7% |
| EPS (diluted) | — | -$4.19 | -$3,093.42 | -$10.26 | — | — |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.25M | -$14.9M | -$16.8M | -$12.7M | -$17.4M | -$14.8M |
| Capital expenditures | $3.00K | — | $18.0K | $0.00 | $298K | $8.00K |
| Free cash flow | -$7.25M | — | -$16.8M | -$12.7M | -$17.6M | -$14.8M |
| Share buybacks | — | — | — | — | $0.00 | $3.19M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $298K | $19.6M | $2.03M | $166K | $19.5M | $14.7M |
| Total assets | $33.4M | $49.6M | $14.5M | $11.9M | $22.6M | $18.3M |
| Total liabilities | $8.96M | $30.8M | $12.7M | $14.6M | $10.8M | $8.43M |
| Long-term debt | — | — | $2.64M | $2.69M | — | — |
| Shareholders' equity | $24.4M | $18.2M | -$113K | -$2.75M | $11.8M | $9.83M |
| Retained earnings | -$39.8M | -$66.5M | -$82.5M | -$94.5M | -$119M | -$130M |
| Shares (wtd avg diluted) | 3.26M | 6.36M | 6.80B | 3.38B | 1.61M | 14.4M |
Every figure is extracted from Allarity Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.